Exploring 2-methyl–substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2

Ryohto Koharazawa, Mayu Hayakawa, Kazuki Takeda, Kotone Miyazaki, Chisato Tode, Yoshihisa Hirota, Yoshitomo Suhara

研究成果: Article査読

抄録

Since the outbreak of the pandemic, various anti-SARS-CoV-2 drugs have been developed. In particular, 3CL protease (3C-like protease, 3CLpro) is an attractive drug target because it is an essential enzyme for viral multiplication and is present only in viruses, not in humans. To date, 3CLpro inhibitors against SARS-CoV-2 such as nirmatrelvir and ensitrelvir have been launched as oral drugs in Japan, but there is still no potent drug against SARS-CoV-2, due to issues of in vivo absorption and stability. Recently, vitamin K3 was reported to show inhibitory activity against 3CLpro of SARS-CoV-2, and the mechanism of action was predicted to be the formation of a covalent bond between the thiol group of cysteine 145, the active center of 3CLpro, and the C-3 position of vitamin K3. Therefore, we synthesized derivatives in which the 2-methyl group of the vitamin K3 was systematically converted to other substituents and examined their inhibitory activity against 3CLpro of SARS-CoV-2. The results showed that the compounds with the sulfide structure showed an approximately 4-fold increase in activity over vitamin K3. These results indicated the possibility of creating new inhibitors based on vitamin K3 and its derivatives.

本文言語English
論文番号129642
ジャーナルBioorganic and Medicinal Chemistry Letters
100
DOI
出版ステータスPublished - 2024 3月 1

ASJC Scopus subject areas

  • 生化学
  • 分子医療
  • 分子生物学
  • 薬科学
  • 創薬
  • 臨床生化学
  • 有機化学

フィンガープリント

「Exploring 2-methyl–substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル